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Abstract  1 
Paracetamol (acetaminophen, APAP) is one of the most commonly used analgesics in the 2 
UK and USA. However, exceeding the maximum recommended dose can cause serious 3 
liver injury and even death. Promising APAP toxicity biomarkers are thought to add value to 4 
those used currently and clarification of the functional relationships between these 5 
biomarkers and liver injury would aid clinical implementation of an improved APAP toxicity 6 
identification framework. The framework currently used to define an APAP overdose is highly 7 
dependent upon time since ingestion and initial dose - information which is often highly 8 
unpredictable. A pharmacokinetic-pharmacodynamic (PK-PD) APAP model has been built in 9 
order to understand the relationships between a panel of biomarkers and APAP dose. 10 
Visualisation and statistical tools have been used to predict initial APAP dose and time since 11 
administration. Additionally, logistic regression analysis has been applied to histology data to 12 
provide a prediction of the probability of liver injury.  13 
 14 
 15 
 16 
  17 
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Introduction  1 
Acetaminophen (paracetamol, APAP) is the most commonly used painkiller in the world (1) 2 
and the leading cause for acute liver failure (ALF) in the Western world (2). The current 3 
antidote used to treat cases of APAP overdose, N-acetylcysteine (NAC), reduces the 4 
likelihood of progression into drug-induced liver injury (DILI) (3). NAC is highly effective 5 
when administered within 8 to 10 hours of initial APAP dose (4). Although NAC is currently 6 
the most effective APAP overdose treatment, there are many adverse side effects such as 7 
rash, vomiting and anaphylactoid reaction (3). The decision to administer NAC is currently 8 
based upon the nomogram treatment line (5) which is influenced by a measurement of 9 
Alanine Aminotransferase (ALT), but is also  heavily dependent on the initial dose amount 10 
and time elapsed since ingestion (6), information which is often highly unpredictable within 11 
the clinical setting.  12 
ALT elevation represents probable liver-injury post-occurrence (7) and is the most widely 13 
used blood-based biomarker for measuring DILI (8). Aspartate Aminotransferase (AST) is 14 
another DILI biomarker (8) that accumulates in the blood due to liver damage, but it is also 15 
linked to other pathologies, e.g. heart injury (9). Increased serum total bilirubin (TBL) is 16 
indicative of the substantial loss of functional hepatocytes; therefore, similar to ALT, this 17 
biomarker does not predict hepatotoxicity potential but instead is a post-occurrence indicator 18 
(7). In order to improve the treatment of APAP-induced DILI via NAC therapy, biomarkers 19 
are required which can predict liver damage a priori. Although there are clear limitations, 20 
clinics currently analyse changes in ALT, AST and TBL in combination to predict DILI (10). 21 
Recently, biomarkers K18 and HMGB1 have been shown to add value to the measurement 22 
of ALT (11) and have the potential to predict DILI pre-occurrence. However, such new 23 
biomarkers are often examined singly and clarification of their functional relationships is 24 
required to aid clinical implementation (12). For a thorough review of the mechanisms of DILI 25 
see, for example, (13). 26 
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In-silico modelling allows for the development of mechanistic understanding of biological 1 
systems which may not always be possible from in-vitro/in-vivo experiments alone. An inter-2 
disciplinary, systems toxicology approach is a cost-effective way of understanding and 3 
predicting drug efficacy and toxicology whilst complying with the 3R’s (scientific framework 4 
for use of animals in research) (14). There have been multiple in-silico models which have 5 
been previously developed to study APAP metabolism and associated toxic potential. Reith 6 
et al. (2009) produced a system of equations with parameters fitted to human data consisting 7 
of patients dosed with pain-relief to provide clarification of the role of the glucuronidation and 8 
sulphation pathways, providing a basis for examining APAP metabolism in various disease 9 
states. Ochoa et al. (16) took a multi-scale approach by firstly creating a spatiotemporal 10 
prediction of drug and metabolite concentrations within the liver, and then, at the whole-body 11 
level, including blood-flow between organs. Remien et al. (17) created a model for 12 
acetaminophen-induced liver damage and derived ordinary differential equations (ODEs) 13 
describing changes  in AST, ALT and INR. The authors optimised initial APAP dose amount 14 
and time since overdose by fitting the resulting ODEs to clinical data (from 53 overdose 15 
patients). Remien et al. (18) then extended this framework to a cell-based model. Our study 16 
extends Remien’s approach by combining ALT with additional biomarkers that have the 17 
potential to predict APAP-induced liver injury pre-occurrence. Additionally, the study is 18 
extended to non-overdose and overdose cases in an attempt to identify the key biomarkers 19 
that discriminate between the two situations. Ben-Shachar et al. (18) created a retrospective 20 
study complementary to Remien’s model. Whilst Remien’s model aimed to predict overdose 21 
occurrence, Ben-Shachar’s model was used to determine whether an overdose would lead 22 
to fatal liver damage. Reddyhoff et al. (20) constructed a cell-based model that described 23 
major pathways impacting on APAP clearance. Sensitivity analysis determined which 24 
parameters had the largest effect on the progression to toxicity. Shoda et al. (21) 25 
mechanistically modelled the biomarker HMGB1. Their focus was the role of HMGB1 with 26 
regards the innate immune response and concluded that HMGB1 was a key input for 27 
immune cell activation.  28 
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In this report, our focus is to investigate HMBG1 within a panel of DILI biomarkers, 1 
attempting to predict APAP toxicity in mice. We propose a novel framework to predict initial 2 
APAP dose, time since administration and the probability of APAP-induced liver injury. The 3 
platform is distinctive primarily due to the use of promising biomarkers, optimised within the 4 
PK/PD framework by combining the use of deterministic modelling with statistical analysis. 5 
The mouse is widely considered to be a good model for APAP toxicity prediction in humans 6 
(22) and we have utilised mouse-derived data in this study to develop our new in-silico 7 
framework by exploiting the rich data sets available and also to avoid, at this early stage of 8 
model development, the uncertainties associated with APAP human overdose data.  9 
Translation to the human clinical case would be, in theory, a relatively simple adjustment of 10 
the PK/PD model parameters, which could be estimated from a Population-11 
Pharmacokinetics (Pop-PK) analysis of clinical overdose data (23). However, the key feature 12 
of this current work is to demonstrate the development and validation of our new predictive 13 
framework using the more amenable mice data. The results from our investigation define 14 
currently undocumented PK parameters for APAP in mice, and the biomarkers are examined 15 
as a panel, rather than individually. Additionally, the focus of this work is the biomarkers that 16 
work well for DILI prediction due to APAP, which may only represent certain pathways or 17 
mechanisms that are not applicable to other drugs but we anticipate that this in-silico 18 
approach can be translated across drug space with the necessary biomarker data. 19 
 20 
Methods 21 
Model development (i) – APAP pharmacokinetics 22 
Four datasets from two separate published studies (24,25) recording APAP concentration 23 
over time in mice following intraperitoneal administration of  50, 150, 500 and 530 mg/kg 24 
doses were used to parameterise a two-compartment pharmacokinetic (PK) model 25 
describing APAP metabolism in mice. Note that for applications to oral administration, the 26 
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absorption rate parameter, 𝑘𝑎, would be multiplied by a bioavailability fraction to implicitly 1 
take into account effects of gastric emptying and absorbed fraction (details of the model 2 
selection can be found in the supplementary material). 3 
Two ordinary differential equations (ODEs) were used to represent changes in APAP 4 
concentration within two PK compartments (central and peripheral) of the mice in the 5 
following system, 6 
 𝑑𝐶𝑐
𝑑𝑡
=
𝑘𝑎𝐷0𝑒
−𝑘𝑎𝑡
𝑉𝑐
+ 𝑘21𝐶𝑝
𝑉𝑝
𝑉𝑐
− 𝑘12𝐶𝑐 − 𝑘𝑒𝑙𝐶𝑐 , (1) 
 𝑑𝐶𝑝
𝑑𝑡
=  𝑘12𝐶𝑐
𝑉𝑐
𝑉𝑝
− 𝑘21𝐶𝑝, (2) 
where 𝐶𝑐  represents the central compartment concentration of APAP (mol/l), 𝐶𝑝 represents 7 
the peripheral compartment concentration of APAP (mol/l), 𝑘𝑎 represents the absorption 8 
rate from the peritoneal cavity (h-1), 𝐷0 represents initial dose (mg), 𝑘21 represents the 9 
transfer rate from the peripheral to the central compartment (h-1), 𝑘12 represents the transfer 10 
rate from the central to the peripheral compartment (h-1), 𝑉𝑝 represents the theoretical 11 
volume of the peripheral compartment (l/kg), 𝑉𝑐 represents the theoretical volume of the 12 
central compartment (l/kg), 𝑘𝑒𝑙 represents the overall elimination rate (summation of both 13 
excretion and metabolism processes) (h-1), and 𝑡 represents the time variable (h). 14 
Solving both equations analytically through Laplace transforms (26) gives the following 15 
equation for paracetamol concentration in the central compartment as a function of time, 16 
𝐶𝑐(𝑡) =
𝑘𝑎𝐷0
𝑉𝑐
[
(𝑘21 −  𝛼)
(𝑘𝑎 −  𝛼)(𝛽 − 𝛼)
𝑒−𝛼𝑡 +
(𝑘21 − 𝛽)
(𝑘𝑎 −  𝛽)(𝛼 − 𝛽)
𝑒−𝛽𝑡 +
(𝑘21 − 𝑘𝑎)
(𝛼 − 𝑘𝑎)(𝛽 − 𝑘𝑎)
𝑒−𝑘𝑎𝑡], (3) 
where 𝛼 and 𝛽 are related to the model parameters as follows, 17 
𝛼 =
1
2
(𝑘12 + 𝑘21 + 𝑘𝑒𝑙 + √(𝑘12 + 𝑘21 + 𝑘𝑒𝑙)2 − 4𝑘21𝑘𝑒𝑙), 
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and 1 
𝛽 =
1
2
(𝑘12 + 𝑘21 + 𝑘𝑒𝑙 − √(𝑘12 + 𝑘21 + 𝑘𝑒𝑙)2 − 4𝑘21𝑘𝑒𝑙). 
Equation (3) was fitted to the four aforementioned datasets simultaneously using a Nelder-2 
Mead search algorithm (27), with parameters 𝑘𝑎, 𝑘21, 𝑉𝑐 , 𝛼 and 𝛽 being optimised in order to 3 
minimise the difference between the model output and the observed APAP dynamics. Note 4 
that all subsequent data fitting also employs this algorithm. Data fitting was performed using 5 
the fminsearch tool in Matlab (28). Optimised parameter values and model simulation code 6 
are provided in the supplementary material. 7 
Model development (ii) – glutathione depletion  8 
The role of glutathione (GSH) in APAP metabolism is to detoxify N-acetyl-p-9 
benzoquinoeimine (NAPQI), a highly reactive metabolite (13) formed following the 10 
bioactivation of APAP. Therefore, GSH stores are depleted in the case of an overdose and 11 
NAPQI accumulates, eventually causing liver damage. In our model, paracetamol biomarker 12 
response dynamics were assumed to be directly dependent on GSH depletion. The GSH 13 
parameter values were optimised such that the solution was fitted to GSH time-course data 14 
from a literature study (25). GSH dynamics are described in the equation below, 15 
 𝑑[𝑔𝑠ℎ]
𝑑𝑡
= 𝑘𝑜 ∙ 𝑔𝑠ℎ0 − 𝑘𝑜 ∙ 𝑔𝑠ℎ −
𝜉 ∙ 𝑘𝑒𝑙 ∙ 𝐶𝑐 ∙ 𝑔𝑠ℎ
𝑔𝑠ℎ + 𝑘𝑝𝑟
, (4) 
where 𝑘𝑜 is the basal removal rate (including background usage) of GSH (h
-1), 𝑔𝑠ℎ0 is the 16 
baseline value of GSH (mol/l) in the APAP-free steady state, 𝜉 is the proportion of 17 
eliminated APAP that is transformed into NAPQI, and 𝑘𝑝𝑟 is the ratio of NAPQI forming other 18 
protein adducts relative to NAPQI detoxified by GSH. The APAP elimination rate, 𝑘𝑒𝑙, was 19 
identified during PK model development (above) whilst all other parameters were optimised 20 
by fitting Equation (4) to the data in Antoine et al. (25). Further information, and full 21 
derivation of the GSH ODE in Equation (4), is described in the supplementary material. 22 
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Model development (iii) – pharmacodynamics 1 
The toxic response to APAP overdose was mathematically described with individual 2 
pharmacodynamic (PD) models representing biomarker concentrations (𝑟 = ALT, HMGB1, 3 
K18 and Fragmented K18) over time, as described in Equation (5), 4 
 𝑑𝑟
𝑑𝑡
= 𝑟0𝑘𝑜𝑢𝑡 (
𝑅50
𝑛 + 𝑔𝑠ℎ0
𝑛
𝑅50
𝑛 ) (1 −
𝑔𝑠ℎ𝑛
𝑅50
𝑛 + 𝑔𝑠ℎ𝑛
) − 𝑘𝑜𝑢𝑡𝑟, (5) 
where 𝑟0 is the biomarker baseline concentration, 𝑘𝑜𝑢𝑡 is the natural decay rate of the 5 
biomarker (h-1), 𝑅50 represents the concentration of (GSH) which causes the biomarker 6 
production (response) to be half its maximal value (mol/l), and 𝑛 is a parameter that reflects 7 
the steepness of the biomarker production term (29). Further model details can be found in 8 
the supplementary material. Whilst parameter values 𝑟0 and 𝑔𝑠ℎ0 can be identified directly 9 
from the data, 𝑘𝑜𝑢𝑡 , 𝑅50 and 𝑛 were optimised by individually fitting the model output to data 10 
measuring biomarker concentration over time following a 530 mg/kg dose of APAP (25). 11 
Model validation 12 
The parameterised PK-PD model was validated against data from a separate experiment 13 
(detailed below). The PK-PD model simulated several dosing scenarios [0,150,300,530] 14 
mg/kg and biomarker concentration outputs were extracted at 5 hours and compared to the 15 
experimental data. Further details and results can be found in the supplementary material 16 
(see Figure S1).  17 
Experimental animal treatment 18 
The protocols described were undertaken in accordance with criteria outlined in a license 19 
granted under the Animals (Scientiﬁc Procedures) Act 1986 and approved by the University 20 
of Liverpool Animal Ethics Committee. Groups of six individual CD-1 male mice (25-35 g) 21 
with free access to food and water were included in the study. For the biomarker time-22 
course, treatment was as previously described (25). For the dose/response data used for 23 
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validation, study animals were administered either a 150, 300 or 530 mg/kg i.p APAP 1 
injection and were euthanized 5 h post-treatment. The 5 h time-point has been used in 2 
previous studies (25), and was chosen here not only because the pathological and 3 
biomarker response has been extensively categorised at this point, but the majority of key 4 
mechanisms (apoptosis, necrosis and inflammation) are also identifiable at this time-point. 5 
Control animals received either 0.9% saline or solvent control in 0.9% saline as appropriate. 6 
Serum ALT activity, HMGB1 and fragmented K18 levels were determined, and GSH content 7 
assessment was carried out on the livers of all animals. Total hepatic glutathione (GSH and 8 
oxidized glutathione) levels and biomarker quantification/characterisation were determined 9 
as described previously (25,30).  10 
Predicting time since administration and initial dose 11 
Multiple linear regression 12 
The in-silico model was used to create virtual datasets for testing and validation 13 
(methodology in supplementary material). A robust multiple linear regression model (31) was 14 
fitted to the in-silico derived data to predict time since administration and initial dose.  15 
Visualisation 16 
Principal component analysis (PCA) (32) and the T-SNE method (33) were applied to 17 
visualise the simulated in-silico datasets with regards to linear combinations of all variables 18 
(APAP and toxicity biomarkers combined) for each in-silico individual.  19 
Classification 20 
Appropriate classes for each dose and time range were identified to see if the time-since-21 
administration and dose amount could be predicted for a new individual within the 22 
population. Various classification techniques (detailed in supplementary material) 23 
appropriate for such a task were used and compared.  24 
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 1 
Predicting probability of liver injury 2 
The biomarker time-course experimental data used to create the PD model (25) also 3 
provided a corresponding histology score for each mouse from the range [0, 1, 2, 3]. These 4 
histology scores were binarised based upon previously published criteria (25). Forward-5 
stepwise binary logistic regression (34) was applied in order to understand the most 6 
significant biomarker, or panel of biomarkers for DILI. The most significant biomarkers were 7 
then used in combination with PK-PD model simulations to predict the DILI probability (35).  8 
Further details of all aforementioned statistical techniques can be found in the 9 
supplementary information.  10 
 11 
Results  12 
Results from the parameter optimisation of the PK-PD models can be seen in Figure 1. Note 13 
that sufficient early time experimental APAP plasma concentrations are currently unavailable 14 
which would verify the accuracy of Tmax and Cmax of the 530-mg dose. Nevertheless, with a 15 
R2 value of 0.8304 for the PK model, and values of 0.7513, 0.9634, 0.7413, and 0.6526 for 16 
the PD models for ALT, HMGB1, K18 and fragmented K18 respectively, it is shown that the 17 
in-silico model recapitulates in-vivo experimental dynamics. Optimised parameters for all of 18 
the PK-PD models can be found in the supplementary material (Table S1).  19 
The 𝑅50 parameter in the biomarker PD models defines a concentration of GSH at which the 20 
biomarker has reached half of its maximal production rate (MPR). For biomarkers ALT, 21 
HMGB1, K18 and fragmented K18, the 𝑅50 values were 227.67, 399.08, 212.87 and 72.09 22 
mol/L respectively. Therefore, in the model, as GSH is depleted from a baseline of 696.91 23 
mol/L (36) and reaches a concentration 399.08 mol/L (42.73% depletion), HMGB1 has 24 
reached half of its MPR and is therefore considered to be the fastest responding biomarker. 25 
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GSH must be further depleted to 227.67 mol/L and 212.87 mol/L (67-69% depletion), 1 
respectively, before biomarkers ALT and K18 reach half of their MPR. Approximately 90% 2 
GSH depletion is required for fragmented K18 to reach half of its MPR in the model.  3 
Identifying time/dose category following APAP dose 4 
Projecting the in-silico derived data on to the principal components and visualising with 5 
respect to time since administration and dose amount, as can be seen in Figure 2 (a)-(b), 6 
allowed classes to be clearly distinguished with minimal level of overlap conﬁrming the 7 
biomarker utility in class prediction. The level of class overlap with respect to dose is 8 
significantly lower. Visualising the data with the T-SNE method (Figure 2 (c)-(d)) enhances 9 
the previous visualisation, in that dose may be separated more accurately. Additionally, the 10 
time-since-administration classes are more separable with the T-SNE method, particularly 11 
with earlier time ranges.    12 
The classification results are consistent across the different methodologies (Table 1). Should 13 
a new observation arise, this framework could predict which ‘time-since-administration’ and 14 
‘dose’ category it should be placed in with 73.7% and 86.5% accuracies respectively. The 15 
results of the linear regression model used to evaluate time since administration and initial 16 
dose, both as continuous variables, are reported in Table 2. In both cases, the model is 17 
signiﬁcant at the 99% conﬁdence level. The R2 values indicate that when predicting time 18 
since administration, approximately 53% of the variance in results can be explained by the 19 
model, whilst when predicting dose approximately 80% of the variation can be explained by 20 
the model. An exact time-since-administration value was able to be predicted with a residual 21 
standard error and accuracy of 3.6 h, whilst an exact dose was predicted with only an error 22 
of 56.81 mg/kg.  23 
Predicting the probability of liver injury following an APAP dose 24 
From the forward-stepwise logistic regression analysis, the model which used HMGB1 25 
concentration alone as a predictor had the highest significance (p-value 0.003). Figure 3 (a)-26 
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(f) represents the fold-changes in biomarker concentrations with respect to time following 1 
various doses. For higher doses, APAP and related toxicity biomarker concentrations are 2 
significantly increased during the time course, whilst GSH is significantly decreased at higher 3 
doses, representing depletion of stores. Figure 3 (g) shows how the probability of serious 4 
liver injury (dependent only on HMGB1 concentration as predicted by the logistic regression 5 
model) changes over time for doses between 0-600 mg/kg. A threshold probability of 0.5 (i.e. 6 
50% liver injury likelihood) was used to determine likeliness of DILI. Any observation within 7 
the white contour boundary is therefore predicted likely to be a concentration representative 8 
of liver injury (i.e. 50% chance). For lower toxic doses, according to the model, HMGB1 9 
concentrations that likely indicate liver injury are most apparent between 5-10 h post-dose. 10 
As the dose increases, the time-frame increases to approximately 5-15 h. Note that 11 
combinations of APAP/ALT and APAP/Full K18 were also significant; therefore, these 12 
biomarker combinations could be investigated in the case of predicting DILI following late 13 
presentation of paracetamol toxicity and prognosis within the 24 h window.  14 
Currently, toxicity is thought to be apparent in mice after a 300 mg/kg dose, shown by the 15 
red line in Figure 3 (g). Our binary logistic regression (model based solely on HMGB1 16 
concentration) states there is more than 50% chance of liver injury at a 200 mg/kg dose, 17 
shown by the white contour in Figure 3 (g). The currently used toxic dose (300 mg/kg) 18 
coincides with around 90% GSH depletion which can be seen in Figure 3 (b). This coincides 19 
with a relationship well known in the literature (13). This toxic level is also the dose at which 20 
fragmented K18 begins to elevate, as shown in Figure 3 (f). The toxic dose proposed by the 21 
in-silico model (200 mg/kg) is the dose at which ALT and full K18 begin to elevate (Figure 3 22 
(c) and Figure 3 (e) respectively) and HMGB1 first reaches peak concentration (Figure 3 23 
(d)).  24 
Visualising the probability of liver injury following an APAP dose 25 
13 
 
Combining the PCA/T-SNE analysis with our proposed framework for predicting the 1 
probability of liver injury allowed the virtual datasets to be visualised not only with regard to 2 
the initial dose and time since ingestion, but also the subsequent probability of liver injury. 3 
With reference to Figure 4, observations with a high probability of liver injury are clearly 4 
clustered within the parameter space and separable from low probability cases. Additional 5 
similar projections (with both the PCA and T-SNE methods), including the estimated 6 
maximum probability of liver injury for each observation, are shown in the supplementary 7 
material.  8 
 9 
Discussion  10 
The current clinical framework for predicting whether or not APAP antidote treatment is 11 
necessary is highly dependent upon information provided by the patient such as when the 12 
dose was taken and in what quantity. This information is often vague and/or unreliable. 13 
Consequently, critically vulnerable patients are often left untreated or, conversely, NAC is 14 
unnecessarily administered. Changes in legislation have already led to an estimated 15 
increased cost of £8.3 million per year due to overused NAC treatment (37). Mathematical 16 
and statistical analysis provide a proof-of-concept tool to predict information with a much 17 
higher level of certainty, based on a panel of promising biomarkers. 18 
We have developed an optimised PK-PD model for APAP and appropriate biomarkers of 19 
liver injury in a systems toxicology approach. The model was used to conduct investigations 20 
within a dosing range of 0-600 mg/kg without any further in-vivo testing. The optimised in-21 
silico framework is suitable for use in further theoretical investigations, providing greater 22 
scope for reducing the dependency on animal testing in toxicity and complying with 3Rs 23 
principles (14). For example, results from our analysis could improve experimental 24 
refinement such as predicting the probability of liver injury and toxicity at 200 mg/kg in mice 25 
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rather than 300 mg/kg. Not only may experimentalists be dosing mice at amounts higher 1 
than necessary, they may also be missing vital information apparent at lower doses.  2 
APAP-induced liver toxicity is thought to occur when GSH depletes by around 80-90% (13), 3 
which coincided with elevated fragmented K18 levels. The in-silico PD model, and its 4 
reported R50 values, suggest that levels of HMGB1, ALT and Full K18 elevate prior to this 5 
depletion level, elevating at 43%, 67% and 69% respectively. As a result, HMGB1 in 6 
particular could be considered as an earlier indicator of DILI. 7 
The identification of more accurate predictions of dose timing and amount, informed by 8 
biomarker concentration samples, will improve nomogram treatment line accuracy (6). 9 
Predictions for the time since administration were successfully categorised into (0-2], (2-5], 10 
(5-10], (10-15], and (15-24]-hour ranges based on APAP, ALT, HMGB1 and full K18 11 
concentration values with 73.7% accuracy. Should this framework be translated to a similar 12 
level of efficiency in the human clinical case, this information will have impact regarding the 13 
determination of the potential liver injury, with less dependency on patient information. 14 
Additionally, an exact value was predicted with an accuracy of 3.6 h. Similarly, initial dose 15 
was able to be classified into [0-200], [201-400], [401-600] mg/kg categories with 86.5% 16 
accuracy and an exact dose predicted with an expected error of ± 56.81 mg/kg. A panel of 17 
biomarker measurements could be used in this manner to provide the dose and time 18 
information, which will identify a (time-dose) point on the liver injury framework, provided in 19 
Figure 3-G, from which one can read off an instantaneous probability of liver injury and how 20 
this probability is predicted to change as time progresses. Obtaining dose and time 21 
information based on biomarker concentrations and combining this with our proposed liver 22 
injury framework shows the utility of these biomarkers in predicting dose amount, time since 23 
ingestion and the subsequent probability of liver injury.  24 
Although ALT concentration is currently used as a clinical measure to inform potential 25 
toxicity, it was found to have the least importance in the regression model for predicting time 26 
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since administration as a continuous variable. Out of all the biomarkers used in the multiple 1 
linear regression analysis, HMGB1 was found to have the highest time-since-administration 2 
model coefficient. This analysis suggests therefore, that not only is HMGB1 an earlier 3 
indicator of DILI, but it is also an important biomarker in accurately predicting the time 4 
elapsed since administration. Furthermore, logistic regression analysis identified HMGB1 as 5 
the most significant predictor for liver injury, in line with recent studies defining HMGB1 as a 6 
more sensitive DILI predictor (38). As noted above, the focus of this work has been the 7 
biomarkers that work well for DILI prediction due to APAP, in which case HMGB1 is 8 
highlighted by our analysis. However, for different drugs, DILI may involve different 9 
mechanisms and, as such, HMGB1 may not perform so well as a singular biomarker but 10 
instead a panel would be more predictive.  11 
While the results from the T-SNE method for visualisation showed clear separation, 12 
particularly with regards to the probability of liver injury, there was a slight overlap in the 13 
time-since-administration and dose plots. This result supports the possibility of defining 14 
further classes through unsupervised methodologies in future investigations. The 15 
classification techniques used provided incredibly high accuracy levels considering the 16 
nature of the problem. A further investigation of interest is the rate of misclassiﬁcation 17 
between the classes with regard to critical errors at the edges of the variable ranges. 18 
The framework proposed has the potential for substantial clinical impact once translated to 19 
human. The analysis was applied to mice due to the relative abundance and quality of data 20 
(especially for toxicity cases) and the quantity of relevant biomarker data required to properly 21 
characterise such a mathematical and statistical predictive framework. Equivalent APAP 22 
clinical data is available but has a tendency to be noisy, sparse and inconsistent. Analysis of 23 
such data would therefore require the significant application of (top-down) Population-24 
Pharmacokinetics (Pop-PK) to unravel the stochasticity of the mixed-effects involved, in 25 
addition to understanding and capturing the mechanisms of the PK-PD problem.  For 26 
example, the relative influence of variation in certain model parameters on quantitative 27 
16 
 
model outputs can be determined by sensitivity analysis, allowing for identification of 1 
mechanistic processes that would require particularly careful consideration when translating 2 
this model to a human clinical Pop-PK framework (see supplementary information for further 3 
details).  4 
An advantage of our study is that the same biomarkers can be measured in both humans 5 
and animals by the same methodologies. Moreover, the model hepatotoxin we have 6 
employed, acetaminophen, is directly comparable between human and mice with respect to 7 
mechanism of toxicity and action of the antidote. The major differences between human and 8 
mouse studies are the mass dose of acetaminophen needed to induced toxicity in mice and 9 
the kinetics of the biomarker profile (25,39,40). The dose response in mice is well 10 
documented and is consistent with our data. Furthermore, this can be adjusted as a 11 
parameter within our model to reflect the clinical situation. There are a number of clinical 12 
studies now published that have measured these biomarkers from human studies in a time-13 
dependent way (41,42). The approach we describe to modify dose adjustment can also be 14 
undertaken to reflect biomarker kinetic differences. It is important to note that it is difficult to 15 
properly obtain or assess human pathology in the acute setting, and it is only really in the 16 
event of liver transplantation that we see a strong relationship between human and mouse 17 
(25,43). Given the strong relationship between the biomarker signatures and mechanism of 18 
APAP action between human and mouse, it would be reasonable to translate findings from 19 
mouse acute data (25,39), to human acute data (11).  Taking these points into consideration, 20 
in its current form, our framework is highly predictive and provides promise for clinical use in 21 
discriminating time since administration, initial dose amount and subsequent probability of 22 
liver injury. This would be a significant application and could instruct the determination of 23 
NAC intervention in patients suspected of APAP overdose. 24 
Clinical assessment of DILI is, in practice, often based on causality assessment, with expert 25 
opinion being the gold standard and does not wholly depend on simple biochemical tests. 26 
We have recently discussed the potential improvement to lab-based measures in aiding DILI 27 
17 
 
assessment and one key feature we propose is that lab measurements should be repeated 1 
when DILI is suspected (11,44). This could allow for the determination of the cause of injury 2 
as well as the derivation of the AUC of a liver toxicity marker. A limitation of our current in-3 
silico model framework is that it is focused on whether or not liver injury occurs, rather than 4 
prediction of the maximum damage observed in an individual. The cause of this limitation is 5 
the sparsity of the histology data used for model parameterisation. However, if such 6 
additional AUC-based measurements could be obtained then this could potentially offer vital 7 
data to extend the predictive potential of our in-silico platform by quantifying the maximal 8 
liver injury and further aiding DILI assessment. 9 
 10 
Study Highlights 11 
What is the current knowledge on the topic?  12 
The current clinical framework for predicting paracetamol overdose is imprecise, 13 
predominantly due to a dependency on uncertain information from patients such as dose 14 
amount and time since administration.  15 
What question did this study address? 16 
Mathematical modelling and statistical methods are applied to predict dose, time since 17 
administration and the probability of paracetamol-induced-liver-injury based on biomarker 18 
information by exploiting the relative abundance and quality of mouse data.  19 
What does this study add to our knowledge? 20 
A new in-silico paracetamol toxicity identification framework is described to simulate the 21 
pharmacokinetic/pharmacodynamic behaviour of paracetamol and a panel of corresponding 22 
toxicity biomarkers with considerable translational potential.  23 
How might this change drug discovery, development, and/or therapeutics? 24 
18 
 
Systems toxicology approaches to direct biomarker identification and optimisation can also 1 
be used to develop predictive modelling frameworks for other hepatotoxic drugs. An 2 
understanding of complex biological system interactions is required to refine potential 3 
treatment strategies and improve safety, ethics and cost-efficiency. Mathematical modelling 4 
provides an enhanced mechanistic understanding while statistical modelling can provide 5 
robust, physiologically relevant predictions to underpin future investigations.  6 
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Figure Legends 1 
Figure 1. In-silico simulation outputs from the optimised model compared with the 2 
experimental data. (a) APAP PK simulations (solid lines) comparable to original data values 3 
with green, black, magenta and red representing APAP time-course following a 50, 150, 500, 4 
and 530 mg/kg dose respectively. (b) GSH simulations (black dashed lines) comparable to 5 
original data (blue). Individual PD simulation (black dashed lines) comparable to data (blue) 6 
for biomarkers ALT (b), HMGB1 (c), Full K18 (d), and Fragmented K18 (e). 7 
Figure 2. Visualisation and classification of time-since-administration and dose results. For 8 
time-since-administration, dark green represents class [0-2), orange represents [2-5), blue 9 
represents [5-10), pink represents [10-15) and pale green represents [15-24) hours. For 10 
dose, green represents [0-200], orange represents [201-400] and blue represents [401-600] 11 
mg/kg.  (a)-(b) 2-dimensional PCA visualisation of in-silico mouse observations with respect 12 
to time since administration and dose respectively. (c)-(d) 2-dimensional TSNE visualisation 13 
of in-silico mouse observations with respect to time since administration and dose 14 
respectively.  15 
Figure 3. (a)-(f) Fold-changes in biomarker concentration relative to their baseline values 16 
over time [0-24] hrs for APAP, GSH, ALT, HMGB1, Full K18 and Fragmented K18 17 
respectively, following APAP doses ranging from 0-600 mg/kg. (g) Proposed framework for 18 
predicting probability of liver injury dependent upon dose, time and HMGB1 concentration. 19 
The white contour indicates the threshold of probability 0.5 of liver injury, the red dashed-line 20 
represents currently used APAP dose for toxicity studies in mice, the white dashed-line 21 
represents toxic dose proposed by our model, the green dashed-line indicates current known 22 
therapeutic dose for mice. 23 
Figure 4: 2-dimensional TSNE visualisation of in-silico mouse observations with respect to 24 
estimated probability of liver injury.  25 
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Table 1: Classification results for several algorithms with respect to time-since-
administration and dose respectively, with numbers representing levels of accuracy. For 
example, the multinomial logistic regression model can predict time since administration with 
72.8% accuracy. 
 
 
 
Classification Method Time Accuracy Dose Accuracy 
Multinomial Logistic Regression 0.728 0.865 
Ordinal Multinomial Logistic Regression 0.570 0.859 
Naïve Bayes 0.689 0.844 
Linear Discriminant Analysis 0.657 0.860 
Quadratic Discriminant Analysis 0.737 0.853 
K-nearest neighbour 0.664 0.859 
Optimal Weighted Nearest Neighbour 0.676 0.858 
  
Table 2: Multiple linear regression analysis results - summary statistics for models used to 
predict both time since administration and dose.  The first number in each element of the 
table represents the biomarker coefficient in the regression model, whilst the second number 
represents the coefficient’s corresponding error. For example, -18.141 is the APAP 
concentration coefficient in the model predicting time since administration, and this 
coefficient has an error of 1.095. The significance of each biomarker in the model is 
indicated by the number of asterisks (see note). 
 
 
 
 Dependent Variable 
(coefficient and related error) 
 
 Time (1) 
 
Dose (2) 
APAP Concentration -18.141*** 
(1.095) 
 
445.602*** 
(13.865) 
ALT concentration 2.402** 
(0.988) 
 
94.724*** 
(12.830) 
HMGB1 concentration -15.928*** 
(0.636) 
 
 
Full K18 concentration 8.964*** 
(0.837) 
 
241.527*** 
(12.958) 
Fragmented K18 concentration  310.574*** 
(13.260) 
 
Constant 14.812*** 
(0.268) 
 
67.068*** 
(3.193) 
Observations 
Residual Std. Error (df == 994) 
1,000 
3.593 
1,000 
56.805 
 
Note: *p<0.1; **p<0.05; ***p<0.01 
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